Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-21

Clinical Trial Update: Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF [Phase 3]

View source ↗

Summary

Phase 3 confirmatory trial of HEC585 tablets for idiopathic pulmonary fibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HEC585 Tablets

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Status: RECRUITING